世界の大腸癌診断・検査装置市場:医療機器パイプライン分析2016

◆英語タイトル:Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
◆商品コード:GDME0218EPD
◆発行会社(調査会社):GlobalData
◆発行日:2016年8月6日
◆ページ数:288
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD8,000 ⇒換算¥912,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD12,000 ⇒換算¥1,368,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、大腸癌診断・検査装置のグローバル製品パイプライン動向について調査・分析し、以下の構成でお届けいたします。
・大腸癌診断・検査装置の概要
・大腸癌診断・検査装置の開発動向:開発段階別分析
・大腸癌診断・検査装置の開発動向:セグメント別分析
・大腸癌診断・検査装置の開発動向:領域別分析
・大腸癌診断・検査装置の開発動向:規制Path別分析
・大腸癌診断・検査装置の開発動向:承認日(推定)別分析
・企業別大腸癌診断・検査装置の開発動向(パイプライン製品、進行中の治験)
・大腸癌診断・検査装置の最近動向
【レポートの概要】

Colorectal Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2016

Summary

GlobalData’s Medical Devices sector report, “Colorectal Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2016″ provides an overview of Colorectal Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Colorectal Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Colorectal Cancer Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Colorectal Cancer Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Colorectal Cancer Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 18
2 Introduction 19
2.1 Colorectal Cancer Diagnostic Tests Overview 19
3 Products under Development 20
3.1 Colorectal Cancer Diagnostic Tests – Pipeline Products by Stage of Development 20
3.2 Colorectal Cancer Diagnostic Tests – Pipeline Products by Territory 21
3.3 Colorectal Cancer Diagnostic Tests – Pipeline Products by Regulatory Path 22
3.4 Colorectal Cancer Diagnostic Tests – Pipeline Products by Estimated Approval Date 23
3.5 Colorectal Cancer – Ongoing Clinical Trials 24
4 Colorectal Cancer Diagnostic Tests – Pipeline Products under Development by Companies 25
4.1 Colorectal Cancer Diagnostic Tests – Pipeline Products by Stage of Development 25
4.2 Colorectal Cancer Diagnostic Tests – Pipeline Products by Stage of Development 30
5 Colorectal Cancer Diagnostic Tests Companies and Product Overview 35
5.1 A2K Technologies Company Overview 35
5.2 Abbott Diagnostics Company Overview 36
5.3 Abcodia Ltd. Company Overview 37
5.4 Acobiom Company Overview 38
5.5 Advanced Marker Discovery, S.L. Company Overview 39
5.6 Advpharma Inc. Company Overview 40
5.7 Ambergen, Inc. Company Overview 41
5.8 Ambrilia Biopharma Inc. Company Overview 43
5.9 Arizona State University Company Overview 44
5.10 ArtemixRx Company Overview 45
5.11 Asuragen, Inc. Company Overview 46
5.12 Bio Mark Ltd Company Overview 47
5.13 Biocartis SA Company Overview 48
5.14 Biodesix Inc. Company Overview 49
5.15 BioMarCare Technologies Ltd. Company Overview 50
5.16 BioMark Diagnostics Inc. Company Overview 52
5.17 BioMarker Strategies, LLC Company Overview 53
5.18 bioMerieux S.A. Company Overview 54
5.19 Biomoda, Inc. (Inactive) Company Overview 56
5.20 Biosceptre (Aust) Pty Ltd Company Overview 57
5.21 BioSystems International Company Overview 59
5.22 Biotechnostics GmbH Company Overview 60
5.23 BioTime, Inc. Company Overview 61
5.24 Biotron Limited Company Overview 63
5.25 Castle Biosciences Incorporated Company Overview 65
5.26 Cellmid Limited Company Overview 66
5.27 Ceres Nanosciences, Inc. Company Overview 68
5.28 Cernostics Inc. Company Overview 69
5.29 China Sky One Medical, Inc. Company Overview 70
5.30 Chronix Biomedical, Inc. Company Overview 71
5.31 Cleveland Diagnostics Inc. Company Overview 72
5.32 ColoPrev Company Overview 73
5.33 Columbia University Company Overview 74
5.34 Courtagen Life Sciences, Inc. Company Overview 75
5.35 CS-Keys, Inc. Company Overview 76
5.36 Di.V.A.L Toscana srl Company Overview 77
5.37 Diadexus Inc Company Overview 78
5.38 DiagnoCure Inc. Company Overview 79
5.39 Diaxonhit S.A. Company Overview 81
5.40 EDP Biotech Corporation Company Overview 83
5.41 Epigenomics AG Company Overview 84
5.42 Eventus Diagnostics, Inc. Company Overview 86
5.43 Exact Sciences Corporation Company Overview 87
5.44 Exiqon A/S Company Overview 90
5.45 Exosomics Siena SpA Company Overview 92
5.46 Fina Biotech Company Overview 93
5.47 GenomicTree, Inc. Company Overview 95
5.48 Ghent University Company Overview 97
5.49 GlycoZym Company Overview 98
5.50 Health Discovery Corporation Company Overview 99
5.51 Human Metabolome Technologies, Inc. Company Overview 101
5.52 Ikonisys, Inc. Company Overview 102
5.53 InterGenetics Incorporated Company Overview 103
5.54 IV Diagnostics, Inc. Company Overview 104
5.55 John Hopkins University Company Overview 105
5.56 Lab21 Limited Company Overview 106
5.57 Laboratorios Alpha San Ignacio Pharma S.L. Company Overview 107
5.58 Lightsphere Diagnostics Company Overview 108
5.59 LX Diagnostics Company Overview 109
5.60 MabCure Inc. Company Overview 110
5.61 Matrix-Bio, Inc. Company Overview 112
5.62 Max-Delbruck-Centrum fur Molekulare Medizin (MDC) Company Overview 115
5.63 MDNA Life Sciences, Inc. Company Overview 116
5.64 MDxHealth SA Company Overview 117
5.65 Merrimack Pharmaceuticals, Inc. Company Overview 119
5.66 Metabiomics Corporation Company Overview 121
5.67 Metabolomic Technologies Inc. Company Overview 122
5.68 Metabolon, Inc. Company Overview 124
5.69 MetaStat, Inc. Company Overview 125
5.70 Milagen, Inc. Company Overview 127
5.71 Miraculins Inc. Company Overview 128
5.72 Mode Dx Ltd. Company Overview 130
5.73 Moscow Institute of Physics and Technology Company Overview 131
5.74 Myriad Genetics, Inc. Company Overview 132
5.75 Nanosphere, Inc. Company Overview 134
5.76 NetScientific Plc Company Overview 136
5.77 Norda ASA Company Overview 137
5.78 Novel Bio-spectrum Technologies, Inc. Company Overview 138
5.79 Nuclea Biotechnologies Inc. Company Overview 139
5.80 Nuvera Biosciences, Inc. Company Overview 140
5.81 Oncimmune (USA) LLC Company Overview 141
5.82 OncoVista Innovative Therapies, Inc. Company Overview 142
5.83 On-Q-ity, Inc. (Inactive) Company Overview 144
5.84 Origin Sciences Limited Company Overview 145
5.85 Orion Genomics LLC Company Overview 146
5.86 OTraces Inc. Company Overview 147
5.87 Oxford Cancer Biomarkers Company Overview 148
5.88 Oxford Gene Technology Limited Company Overview 151
5.89 Panacea Pharmaceuticals, Inc. Company Overview 152
5.90 PleX Diagnostics Company Overview 153
5.91 Precision Biologics, Inc. Company Overview 154
5.92 Prediction Sciences Company Overview 157
5.93 Protagen AG Company Overview 158
5.94 Rabin Medical Center Company Overview 159
5.95 Rosetta Genomics Ltd Company Overview 160
5.96 Scienion AG Company Overview 162
5.97 Seegene, Inc. Company Overview 164
5.98 Shuwen Biotech Co. Ltd. Company Overview 166
5.99 Siamab Therapeutics, Inc. Company Overview 167
5.100 Skuldtech France Company Overview 168
5.101 Sysmex Corporation Company Overview 169
5.102 Tel Aviv University Company Overview 170
5.103 The Chinese University of Hong Kong Company Overview 171
5.104 The Walter and Eliza Hall Institute of Medical Research Company Overview 173
5.105 TheraDiag SA Company Overview 175
5.106 Theranostics Health, Inc. Company Overview 180
5.107 Todos Medical Company Overview 181
5.108 Universal Diagnostics, S. L. Company Overview 182
5.109 Universite De Lyon Company Overview 183
5.110 University of Alabama at Birmingham Company Overview 184
5.111 University of Illinois at Chicago Company Overview 188
5.112 University of Texas at Austin Company Overview 189
5.113 US Biomarkers, Inc. Company Overview 190
5.114 Vanderbilt University Company Overview 191
5.115 Vermillion, Inc. Company Overview 193
5.116 Viomics Inc. Company Overview 195
5.117 Vitatex Inc. Company Overview 196
5.118 VolitionRX Ltd. Company Overview 197
5.119 XEPTAGEN SpA Company Overview 203
6 Colorectal Cancer Diagnostic Tests – Recent Developments 205
6.1 Aug 02, 2016: Genomic Health Reports Continued Double-Digit Growth in Announcement of Second Quarter 2016 Financial Results, Raises Low End of Full-Year Test and Revenue Guidance 205
6.2 Jul 28, 2016: Exact Sciences Prices Public Offering of Shares for USD132 Million 206
6.3 Jul 28, 2016: Merck Enters into Co-Development Agreement with Amoy Diagnostics 207
6.4 Jul 28, 2016: Illumina Names Philip W. Schiller to its Board of Directors 207
6.5 Jul 28, 2016: PRA Health Sciences Reports Second Quarter 2016 Results 207
6.6 Jul 28, 2016: SCIENION and Applied Microarrays announce a strategic partnership to deliver next generation medical devices 208
6.7 Jul 27, 2016: VolitionRx Granted Fourth U.S. Patent 209
6.8 Jul 26, 2016: Exact Sciences Completes 54,000 Cologuard Tests during the Second Quarter 210
6.9 Jul 26, 2016: NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016 211
6.10 Jul 26, 2016: Illumina Reports Financial Results for Second Quarter of Fiscal Year 2016 212
6.11 Jul 20, 2016: Protagen Appoints Bernhard Kirschbaum as New Chairman and Oliver Schacht as New Board Member 214
6.12 Jul 19, 2016: SpectraScience Appoints AMG as Exclusive Distributor in Middle East 214
6.13 Jul 18, 2016: bioMerieux – Second-Quarter 2016 Business Review 214
6.14 Jul 13, 2016: NCQA Proposes Inclusion of Cologuard in 2017 HEDIS Quality Measures 217
6.15 Jul 13, 2016: Biodesix Raises USD6 Million in Venture Financing 218
6.16 Jul 13, 2016: Nasdaq Copenhagen accepts Exiqon request for delisting and cancellation from trading of the Exiqon shares 218
6.17 Jul 11, 2016: THERADIAG Appoints Vincent Fert to Theradiag’s Board of Directors 218
6.18 Jul 08, 2016: Researchers Design Blood Test To Determine Colon Cancer Treatment 219
6.19 Jul 07, 2016: IntegraGen reports strong revenue growth during first half of 2016 219
6.20 Jul 07, 2016: Enzo Biochem’s Life Sciences Unit Reaches $21 Million Patent Infringement Settlement in Delaware With Illumina 220
6.21 Jul 06, 2016: Walter and Eliza Hall Research Institute Scientists Announces An end to ‘futile’ chemotherapy in sight 220
6.22 Jul 05, 2016: Theradiag: Very strong revenue growth in the first half of 2016: +36% 221
6.23 Jul 04, 2016: Exiqon – Nomination of candidates for the supervisory board 222
6.24 Jun 30, 2016: Supervisory Board of Epigenomics appoints Gregory Hamilton as Chief Executive Officer (CEO) 222
6.25 Jun 30, 2016: Merck Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance 222
6.26 Jun 27, 2016: ADL Launches Revolutionary Urine-Based Diagnostic Test To Detect Precursor To Deadly Colorectal Cancer 223
6.27 Jun 24, 2016: VolitionRx Appoints Dr. Edward Futcher to Board of Directors 223
6.28 Jun 23, 2016: Oncimmune Appoints Julian Hirst as Non-Executive Director 225
6.29 Jun 15, 2016: Exact Sciences’ Cologuard Included in Final USPSTF Colorectal Cancer Screening Recommendations 225
6.30 Jun 15, 2016: GeneNews Announces Filing of Q1-2016 Financial Results 226
6.31 Jun 10, 2016: Netscientific Confirms Start Date for Ian Postlethwaite as CFO 227
6.32 Jun 10, 2016: Diadexus to File Chapter 7 227
6.33 Jun 09, 2016: Liquid biopsy test – GATCLIQUID ONCOTARGET – expanded to cover blood cancers such as acute myeloid leukaemia 228
6.34 Jun 03, 2016: Exact Sciences Appoints Jeff Elliott to Lead Business Development & Strategy 229
6.35 Jun 02, 2016: Illumina Appoints Paula Dowdy Senior Vice President and General Manager of Commercial Operations for Europe, the Middle East and Africa 229
6.36 May 27, 2016: GeneNews Announces Full Year 2015 Financial Results 230
6.37 May 26, 2016: MetaStat Raises USD0.5 Million in Venture Financing 231
6.38 May 26, 2016: Cellmid provides update on Japanese sale 231
6.39 May 23, 2016: Epigenomics Announces 2016 First Quarter Financial Results and Reports on Operational Highlights 231
6.40 May 19, 2016: VolitionRx to Present Data Demonstrating Accuracy of NuQ Blood Test in Detecting Colorectal Cancer at World Endoscopy Organization (WEO) Meeting 232
6.41 May 19, 2016: GeneNews Announces a Further Extension of the TSX’s Remedial Review Process 234
6.42 May 17, 2016: Cancer Prevention and Research Institute of Texas Marks Progress at the Halfway Point of its Funding 234
6.43 May 16, 2016: Nanosphere Announces First Quarter Results 236
6.44 May 16, 2016: Vermillion Reports First Quarter 2016 Results 236
6.45 May 16, 2016: Vermillion Reports Fourth Quarter and Full Year 2015 Results 237
6.46 May 13, 2016: VolitionRx Announces First Quarter 2016 Financial Results and Business Update 238
6.47 May 10, 2016: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 240
6.48 May 09, 2016: Castle Biosciences Announces the Appointment of Bernhard E. Spiess as Chief Operating Officer 242
6.49 May 09, 2016: Significant Scientific Appointment for Cellmid Advisory Board Chair 243
6.50 May 04, 2016: Atlantic Diagnostic Labs Enters into Licensing Agreement with Metabolomic Technologies 243
6.51 May 04, 2016: Genomic Health Reports Double-Digit Revenue and Test Growth in Announcement of First Quarter 2016 Financial Results 243
6.52 May 03, 2016: Exact Sciences Completes 40,000 Cologuard Tests during First Quarter 2016 244
6.53 May 02, 2016: China FDA names Epigenomics’ blood-based Septin9 colorectal cancer test a most innovative medical product for 2015 245
6.54 Apr 27, 2016: PRA Health Sciences Reports First Quarter 2016 Results and Updates 2016 Guidance 246
6.55 Apr 18, 2016: LifeLabs Announces Extended Hours of Service in St. Thomas 247
6.56 Apr 07, 2016: VolitionRx Announces CE Mark for NuQ T003 Blood Assay for Detection of Colorectal Cancer 247
6.57 Apr 07, 2016: VolitionRx Announces CE Mark for NuQ V001 for Detection of Colorectal Cancer 249
6.58 Mar 23, 2016: Clinical Genomics Technologies Raises USD11.4 Million in Series A Financing Round 251
6.59 Mar 15, 2016: Theradiag presents at JFHOD the results of a microRNA signature predicting a patient’s therapeutic response in locally advanced rectal cancer 251
6.60 Mar 07, 2016: Institute for Quality Management in Healthcare Assessment and Accreditation 251
6.61 Feb 26, 2016: Online video and print article present ColoMarker study results by BF Overholt MD 252
6.62 Feb 25, 2016: Anthem BCBS Georgia and Virginia Contracted to Cover Cologuard as In-Network Service 252
6.63 Feb 24, 2016: PRA Health Sciences Reports Fourth Quarter and Full Year 2015 Results and Provides 2016 Guidance 253
6.64 Feb 23, 2016: Modeling Data Supports Cologuard Use Every Three Years 254
6.65 Feb 22, 2016: New Canadian recommendation against colonoscopy for routine screening of colorectal cancer 255
6.66 Feb 19, 2016: Routine Annual Screening for Colorectal Cancer Not Achieved by Fecal Blood Tests 255
6.67 Feb 17, 2016: VolitionRx Demonstrates 75% Accuracy in Detecting Highest-Risk Pre-Cancerous Colorectal Adenomas with NuQ Blood Test 256
6.68 Feb 11, 2016: Targeted Diagnostics Raises USD0.7 Million Financing 258
6.69 Feb 10, 2016: Genomic Health Announces 2016 Financial Outlook and Provides 2015 Fourth Quarter and Year-End Financial Results 258
6.70 Jan 21, 2016: Clinical Genomics to Present Data Supporting Utility of 2-Gene Blood Test for Colorectal Cancer Recurrence at ASCO GI 259
6.71 Jan 20, 2016: Biomarker predicts which stage II colon cancer patients may benefit from chemotherapy 260
6.72 Jan 20, 2016: New Biomarker Identifies Colon Cancer Patients Who May Benefit from Chemotherapy 261
6.73 Jan 11, 2016: Exact Sciences Announces Contract with Anthem BlueCross of California 262
6.74 Jan 11, 2016: New Modeling Supports Using Cologuard Every Three Years 263
6.75 Dec 02, 2015: CMS Corrects 2016 Reimbursement Rate for Cologuard 263
6.76 Dec 02, 2015: Cynvenio Biosystems Enters into Agreement with University of Southern Denmark 264
6.77 Dec 01, 2015: Sysmex Establishes New Subsidiary in Ghana – Reinforcing the Company’s Business Foundation in the Markets of West and Central Africa 264
6.78 Nov 30, 2015: med fusion Expands Molecular Diagnostic Test Menu 265
6.79 Nov 24, 2015: Vela Diagnostics Enters into Agreement with Gustave Roussy Institute of Oncology 265
6.80 Nov 17, 2015: PRA Health Sciences Expands Operations in Singapore 265
6.81 Nov 09, 2015: Colorectal screening project to start in Russia with Biohit Oyj’s ColonView test 266
6.82 Nov 03, 2015: Genomic Health Reports Highest Test Growth in Two Years in Announcement of Third Quarter 2015 Financial Results 266
6.83 Nov 02, 2015: PRA Health Sciences Reports Third Quarter 2015 Results And Provides Updated 2015 Guidance 267
6.84 Oct 30, 2015: Stool DNA test accurate in screening for colorectal cancer in Alaska Native people 269
6.85 Oct 28, 2015: New Study Bolsters Cologuard’s Performance in Detecting Colorectal Cancer and Ability to Improve Access to Screening 270
6.86 Oct 19, 2015: Stool DNA Screening Technology to be Featured at ACG 2015 271
6.87 Oct 13, 2015: UCLA Health Implements Tumor DNA Profiling using GenomOncology’s GO Clinical Workbench 271
6.88 Oct 05, 2015: Cologuard Included as Alternative Screening Test under Draft USPSTF Guidelines 272
6.89 Sep 28, 2015: CMS Issues Preliminary Determination Maintaining Cologuard Reimbursement Rate 273
6.90 Sep 22, 2015: VolitionRx Announces CE Mark For NuQ Blood Assay For Detection Of Colorectal Cancer 273
6.91 Sep 15, 2015: Sysmex to Expand U.S. Reagent Factory – Aiming to Meet Growing Demand in the Americas 274
6.92 Sep 09, 2015: VolitionRx Demonstrates NuQ Blood Test Detects 81% of Colorectal Cancers and 67% of High Risk Adenomas in Large Double Blinded Clinical Trial 274
6.93 Sep 08, 2015: Exact Sciences Announces Blue Cross Blue Shield of Rhode Island to Cover Cologuard 276
6.94 Sep 08, 2015: Cynvenio Biosystems Receives Accreditation From College of American Pathologists 277
6.95 Aug 31, 2015: Published Trial Results Indicate High Sensitivity and Reproducibility of Early Colon Cancer Detection by ColoMarker Blood Test 277
6.96 Aug 26, 2015: Exact Sciences Highlights CMS Advisory Panel’s Unanimous Vote to Maintain Medicare Reimbursement Rate for Cologuard 278
6.97 Aug 24, 2015: New Blood Test for Colon Cancer Improves Colonoscopy Screening Results 278
6.98 Aug 19, 2015: Exact Sciences Wins Wisconsin Innovation Award 279
6.99 Aug 12, 2015: Chemimage Receives NIH Grant To Develop Blood Test For Early Detection Of Colorectal Cancer 280
7 Appendix 282
7.1 Methodology 282
7.2 About GlobalData 284
7.3 Contact Us 284
7.4 Disclaimer 285

1.1 List of Tables
Table 1: Colorectal Cancer Diagnostic Tests - Pipeline Products by Stage of Development 23
Table 2: Colorectal Cancer Diagnostic Tests - Pipeline Products by Territory 24
Table 3: Colorectal Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 25
Table 4: Colorectal Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 26
Table 5 Colorectal Cancer Diagnostic Tests - Ongoing Clinical Trials 27
Table 6: Colorectal Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 28
Table 7: Colorectal Cancer Diagnostic Tests - Pipeline Products by Stage of Development 33
Table 8: A2K Technologies Pipeline Products & Ongoing Clinical Trials Overview 38
Table 9: Colospec - Product Status 38
Table 10: Colospec - Product Description 38
Table 11: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 39
Table 12: RealTime mS9 Colorectal Cancer Test - Product Status 39
Table 13: RealTime mS9 Colorectal Cancer Test - Product Description 39
Table 14: Abcodia Ltd. Pipeline Products & Ongoing Clinical Trials Overview 40
Table 15: Diagnostic Assay - Colorectal Cancer - Product Status 40
Table 16: Diagnostic Assay - Colorectal Cancer - Product Description 40
Table 17: Acobiom Pipeline Products & Ongoing Clinical Trials Overview 41
Table 18: Diagnostic Assay - Colon Cancer - Product Status 41
Table 19: Diagnostic Assay - Colon Cancer - Product Description 41
Table 20: Advanced Marker Discovery, S.L. Pipeline Products & Ongoing Clinical Trials Overview 42
Table 21: Screening Test - Colon Cancer - Product Status 42
Table 22: Screening Test - Colon Cancer - Product Description 42
Table 23: Advpharma Inc. Pipeline Products & Ongoing Clinical Trials Overview 43
Table 24: Molecular Diagnostic Biomarker - Colorectal Cancer - Product Status 43
Table 25: Molecular Diagnostic Biomarker - Colorectal Cancer - Product Description 43
Table 26: Ambergen, Inc. Pipeline Products & Ongoing Clinical Trials Overview 44
Table 27: Veracode - Colorectal Cancer - Product Status 44
Table 28: Veracode - Colorectal Cancer - Product Description 45
Table 29: Ambrilia Biopharma Inc. Pipeline Products & Ongoing Clinical Trials Overview 46
Table 30: Colopath/ColorectAlert - Product Status 46
Table 31: Colopath/ColorectAlert - Product Description 46
Table 32: Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 47
Table 33: Biomarker Test - Colorectal Cancer - Product Status 47
Table 34: Biomarker Test - Colorectal Cancer - Product Description 47
Table 35: ArtemixRx Pipeline Products & Ongoing Clinical Trials Overview 48
Table 36: ArtemixRx Prognostic Test - Colon Cancer - Product Status 48
Table 37: ArtemixRx Prognostic Test - Colon Cancer - Product Description 48
Table 38: Asuragen, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49
Table 39: Molecular Diagnostic Assay - Colon Cancer - Product Status 49
Table 40: Molecular Diagnostic Assay - Colon Cancer - Product Description 49
Table 41: Bio Mark Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
Table 42: Diagnostic Test - Colorectal Adenoma - Product Status 50
Table 43: Diagnostic Test - Colorectal Adenoma - Product Description 50
Table 44: Biocartis SA Pipeline Products & Ongoing Clinical Trials Overview 51
Table 45: MSI-Biomarker Diagnostic Test - Colorectal Cancer - Product Status 51
Table 46: MSI-Biomarker Diagnostic Test - Colorectal Cancer - Product Description 51
Table 47: Biodesix Inc. Pipeline Products & Ongoing Clinical Trials Overview 52
Table 48: VeriStrat - Colorectal Cancer - Product Status 52
Table 49: VeriStrat - Colorectal Cancer - Product Description 52
Table 50: BioMarCare Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53
Table 51: Colon MarCarePlex - Product Status 53
Table 52: Colon MarCarePlex - Product Description 53
Table 53: mCRC-Strat - Product Status 54
Table 54: mCRC-Strat - Product Description 54
Table 55: BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 55
Table 56: Metabolomics-based Diagnostic Assay - Colorectal Cancer - Product Status 55
Table 57: Metabolomics-based Diagnostic Assay - Colorectal Cancer - Product Description 55
Table 58: BioMarker Strategies, LLC Pipeline Products & Ongoing Clinical Trials Overview 56
Table 59: Ex Vivo Biomarker Test - Colon Cancer - Product Status 56
Table 60: Ex Vivo Biomarker Test - Colon Cancer - Product Description 56
Table 61: bioMerieux S.A. Pipeline Products & Ongoing Clinical Trials Overview 57
Table 62: Diagnostic Test - Colorectal Cancer - Product Status 57
Table 63: Diagnostic Test - Colorectal Cancer - Product Description 58
Table 64: Biomoda, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 59
Table 65: CyPath Diagnostic Assay - Colorectal Cancer - Product Status 59
Table 66: CyPath Diagnostic Assay - Colorectal Cancer - Product Description 59
Table 67: Biosceptre (Aust) Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 60
Table 68: Colorectal Cancer IHC Diagnostic Test - Product Status 60
Table 69: Colorectal Cancer IHC Diagnostic Test - Product Description 61
Table 70: BioSystems International Pipeline Products & Ongoing Clinical Trials Overview 62
Table 71: Diagnostic Test - Colon Cancer - Product Status 62
Table 72: Diagnostic Test - Colon Cancer - Product Description 62
Table 73: Biotechnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 63
Table 74: Diagnostic Test - Colorectal Cancer - Product Status 63
Table 75: Diagnostic Test - Colorectal Cancer - Product Description 63
Table 76: BioTime, Inc. Pipeline Products & Ongoing Clinical Trials Overview 64
Table 77: PanC-Dx - Colon Cancer - Product Status 64
Table 78: PanC-Dx - Colon Cancer - Product Description 65
Table 79: Biotron Limited Pipeline Products & Ongoing Clinical Trials Overview 66
Table 80: C-Test - Colorectal Cancer - Product Status 66
Table 81: C-Test - Colorectal Cancer - Product Description 67
Table 82: Castle Biosciences Incorporated Pipeline Products & Ongoing Clinical Trials Overview 68
Table 83: DecisionDx- Rectal Cancer - Product Status 68
Table 84: DecisionDx- Rectal Cancer - Product Description 68
Table 85: Cellmid Limited Pipeline Products & Ongoing Clinical Trials Overview 69
Table 86: MK-ELISA Assay - Colorectal Cancer - Product Status 69
Table 87: MK-ELISA Assay - Colorectal Cancer - Product Description 70
Table 88: MK-ELISA Assay - Metastatic Colorectal Cancer - Product Status 70
Table 89: MK-ELISA Assay - Metastatic Colorectal Cancer - Product Description 70
Table 90: Ceres Nanosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 71
Table 91: Nanotrap Colon Cancer Biomarker Test - Product Status 71
Table 92: Nanotrap Colon Cancer Biomarker Test - Product Description 71
Table 93: Cernostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 72
Table 94: TissueCypher Colon Cancer Test - Product Status 72
Table 95: TissueCypher Colon Cancer Test - Product Description 72
Table 96: China Sky One Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 73
Table 97: Diagnostic Kit - Rectum Cancer - Product Status 73
Table 98: Diagnostic Kit - Rectum Cancer - Product Description 73
Table 99: Chronix Biomedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 74
Table 100: Companion Diagnostic Test - Colorectal Cancer - Product Status 74
Table 101: Companion Diagnostic Test - Colorectal Cancer - Product Description 74
Table 102: Cleveland Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 75
Table 103: Blood-Based Diagnostic Test - Colon Cancer - Product Status 75
Table 104: Blood-Based Diagnostic Test - Colon Cancer - Product Description 75
Table 105: ColoPrev Pipeline Products & Ongoing Clinical Trials Overview 76
Table 106: Blood-Based Diagnostic Test - Colorectal Cancer - Product Status 76
Table 107: Blood-Based Diagnostic Test - Colorectal Cancer - Product Description 76
Table 108: Columbia University Pipeline Products & Ongoing Clinical Trials Overview 77
Table 109: IGFBP-3 Diagnostic Test - Product Status 77
Table 110: IGFBP-3 Diagnostic Test - Product Description 77
Table 111: Courtagen Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 78
Table 112: Colorectal Cancer Diagnostic Panel - Product Status 78
Table 113: Colorectal Cancer Diagnostic Panel - Product Description 78
Table 114: CS-Keys, Inc. Pipeline Products & Ongoing Clinical Trials Overview 79
Table 115: caPCNA - Colorectal Cancer - Product Status 79
Table 116: caPCNA - Colorectal Cancer - Product Description 79
Table 117: Di.V.A.L Toscana srl Pipeline Products & Ongoing Clinical Trials Overview 80
Table 118: NanoMabKv - Colorectal Cancer - Product Status 80
Table 119: NanoMabKv - Colorectal Cancer - Product Description 80
Table 120: Diadexus Inc Pipeline Products & Ongoing Clinical Trials Overview 81
Table 121: TRAIL-R2 Assay - Product Status 81
Table 122: TRAIL-R2 Assay - Product Description 81
Table 123: DiagnoCure Inc. Pipeline Products & Ongoing Clinical Trials Overview 82
Table 124: Colorectal/GCC Monitoring Test - Product Status 82
Table 125: Colorectal/GCC Monitoring Test - Product Description 83

1.2 List of Figures
Figure 1: Colorectal Cancer Diagnostic Tests - Pipeline Products by Stage of Development 23
Figure 2: Colorectal Cancer Diagnostic Tests - Pipeline Products by Territory 24
Figure 3: Colorectal Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 25
Figure 4: Colorectal Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 26
Figure 5: Colorectal Cancer Diagnostic Tests - Ongoing Clinical Trials 27

【掲載企業】

A2K Technologies
Abbott Diagnostics
Abcodia Ltd.
Acobiom
Advanced Marker Discovery, S.L.
Advpharma Inc.
Ambergen, Inc.
Ambrilia Biopharma Inc.
Arizona State University
ArtemixRx
Asuragen, Inc.
Bio Mark Ltd
Biocartis SA
Biodesix Inc.
BioMarCare Technologies Ltd.
BioMark Diagnostics Inc.
BioMarker Strategies, LLC
bioMerieux S.A.
Biomoda, Inc.
Biosceptre (Aust) Pty Ltd
BioSystems International
Biotechnostics GmbH
BioTime, Inc.
Biotron Limited
Castle Biosciences Incorporated
Cellmid Limited
Ceres Nanosciences, Inc.
Cernostics Inc.
China Sky One Medical, Inc.
Chronix Biomedical, Inc.
Cleveland Diagnostics Inc.
ColoPrev
Columbia University
Courtagen Life Sciences, Inc.
CS-Keys, Inc.
Di.V.A.L Toscana srl
Diadexus Inc
DiagnoCure Inc.
Diaxonhit S.A.
EDP Biotech Corporation
Epigenomics AG
Eventus Diagnostics, Inc.
Exact Sciences Corporation
Exiqon A/S
Exosomics Siena SpA
Fina Biotech
GenomicTree, Inc.
Ghent University
GlycoZym
Health Discovery Corporation
Human Metabolome Technologies, Inc.
Ikonisys, Inc.
InterGenetics Incorporated
IV Diagnostics, Inc.
John Hopkins University
Lab21 Limited
Laboratorios Alpha San Ignacio Pharma S.L.
Lightsphere Diagnostics
LX Diagnostics
MabCure Inc.
Matrix-Bio, Inc.
Max-Delbruck-Centrum fur Molekulare Medizin (MDC)
MDNA Life Sciences, Inc.
MDxHealth SA
Merrimack Pharmaceuticals, Inc.
Metabiomics Corporation
Metabolomic Technologies Inc.
Metabolon, Inc.
MetaStat, Inc.
Milagen, Inc.
Miraculins Inc.
Mode Dx Ltd.
Moscow Institute of Physics and Technology
Myriad Genetics, Inc.
Nanosphere, Inc.
NetScientific Plc
Norda ASA
Novel Bio-spectrum Technologies, Inc.
Nuclea Biotechnologies Inc.
Nuvera Biosciences, Inc.
Oncimmune (USA) LLC
OncoVista Innovative Therapies, Inc.
On-Q-ity, Inc.
Origin Sciences Limited
Orion Genomics LLC
OTraces Inc.
Oxford Cancer Biomarkers
Oxford Gene Technology Limited
Panacea Pharmaceuticals, Inc.
PleX Diagnostics
Precision Biologics, Inc.
Prediction Sciences
Protagen AG
Rabin Medical Center
Rosetta Genomics Ltd
Scienion AG
Seegene, Inc.
Shuwen Biotech Co. Ltd.
Siamab Therapeutics, Inc.
Skuldtech France
Sysmex Corporation
Tel Aviv University
The Chinese University of Hong Kong
The Walter and Eliza Hall Institute of Medical Research
TheraDiag SA
Theranostics Health, Inc.
Todos Medical
Universal Diagnostics, S. L.
Universite De Lyon
University of Alabama at Birmingham
University of Illinois at Chicago
University of Texas at Austin
US Biomarkers, Inc.
Vanderbilt University
Vermillion, Inc.
Viomics Inc.
Vitatex Inc.
VolitionRX Ltd.
XEPTAGEN SpA

【レポートのキーワード】

大腸癌診断・検査装置

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[世界の大腸癌診断・検査装置市場:医療機器パイプライン分析2016]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月11日現在 219,328 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆